Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer’s Amyloid-β Oligomers in Mice

Considerable clinical and epidemiological evidence links Alzheimer’s disease (AD) and depression. However, the molecular mechanisms underlying this connection are largely unknown. We reported recently that soluble Aβ oligomers (AβOs), toxins that accumulate in AD brains and are thought to instigate synapse damage and memory loss, induce depressive-like behavior in mice. Here, we report that the mechanism underlying this action involves AβO-induced microglial activation, aberrant TNF-α signaling, and decreased brain serotonin levels. Inactivation or ablation of microglia blocked the increase in brain TNF-α and abolished depressive-like behavior induced by AβOs. Significantly, we identified serotonin as a negative regulator of microglial activation. Finally, AβOs failed to induce depressive-like behavior in Toll-like receptor 4-deficient mice and in mice harboring a nonfunctional TLR4 variant in myeloid cells. Results establish that AβOs trigger depressive-like behavior via a double impact on brain serotonin levels and microglial activation, unveiling a cross talk between brain innate immunity and serotonergic signaling as a key player in mood alterations in AD.

**Key words:** Alzheimer’s; depression; inflammation; microglia; serotonin

**Significance Statement**
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the main cause of dementia in the world. Brain accumulation of amyloid-β oligomers (AβOs) is a major feature in the pathogenesis of AD. Although clinical and epidemiological data suggest a strong connection between AD and depression, the underlying mechanisms linking these two disorders remain largely unknown. Here, we report that aberrant activation of the brain innate immunity and decreased serotonergic tonus in the brain are key players in AβO-induced depressive-like behavior in mice. Our findings may open up new possibilities for the development of effective therapeutics for AD and depression aimed at modulating microglial function.

**Introduction**
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the main cause of dementia in the elderly. Brain inflammation is a neuropathological hallmark of AD and is recapitulated in experimental models of the disease (Heneka et al., 2014, 2015; Santos et al., 2016). Soluble oligomers of the amyloid-β peptide (AβOs), toxins that accumulate in the AD brain and are thought to trigger synapse failure and memory loss, have been implicated in key aspects of the pathogenesis of AD (Ferreira and Klein, 2011; Selkoe, 2011; Mucke and Selkoe, 2012; Benilova and De Strooper, 2013). We reported recently that
AβOs trigger proinflammatory pathways, including astrocyte and microglial activation, in the brains of mice and nonhuman primates (Bomfim et al., 2012; Ledo et al., 2013; Lourenço et al., 2013; Forny-Germaino et al., 2014) and that AβO-induced inflammatory signaling causes memory loss in mice (Lourenço et al., 2013).

Although most studies in AD have investigated mechanisms leading to memory/cognitive impairment, other symptoms that are an integral part of the disease have been relatively overlooked. Mood disturbances, including depression, have been reported to affect up to 90% of AD patients (Lyketsos and Olin, 2002) and are considered major risk factors for AD (Green et al., 2003; Ownby et al., 2006; Starkstein and Mizrahi, 2006; Geerlings et al., 2008). Given the complex nature of AD, a deeper understanding of mechanisms underlying major disease symptoms, including behavioral and mood disturbances, may contribute to the development of novel and successful therapies. We recently reported a molecular link between AD and depression by demonstrating that AβOs induce both memory impairment and depressive-like behavior in mice (Ledo et al., 2013). Here, we aimed to determine the molecular mechanisms underlying the effects of AβOs on behavioral abnormalities in mice. We hypothesized that AβO-induced depressive-like behavior is caused by an inflammatory response triggered by microglial activation. To test this hypothesis, we investigated the molecular and functional outcomes of intracerebroventricular infusion of AβOs in mice. Showing that microglia-derived TNF-α signaling triggers depressive-like behavior, inactivation/ablation of microglia or blockade of TNF-α with a neutralizing antibody prevented the behavioral impact of AβOs. Importantly, AβOs decreased brain serotonin (5-HT) levels in mice, whereas treatment with 5-HT prevented AβO-induced microglial activation and increase in TNF-α levels. Results thus reveal a novel modulatory role of 5-HT in brain inflammation. Further, AβOs failed to reduce 5-HT levels or induce depressive-like behavior in Toll-like receptor 4-knockout (TLR4−/−) mice and in chimeric mice harboring a nonfunctional TLR4 in cells of myeloid origin. This implicates microglial TLR4 as a novel and functionally relevant target of AβOs, triggering an inflammatory response that includes increased production and release of TNF-α and leading to depressive-like behavior in mice.

Materials and Methods

Reagents. 5-HT, 1,1,3,3,3,hexafluoro-2-propanol (HFIP), dimethyl sulfoxide (DMSO), and poly-L-lysine were from Sigma-Aldrich. Culture media/reagents, Alexa Fluor-labeled secondary antibodies, and ProLong antifade reagent were from Invitrogen. BCA protein assay kit was from Pierce. Antibody against Iba-1 was from Wako, and anti-F4/80 was from AbD Serotec. Synthetic Aβ1–42 was from American Peptide. Plasma sTNFR-1 levels in human subjects. Blood samples from AD patients or age- and sex-matched controls were from the Pietta study (Caramelli et al., 2011). Study participants were submitted to a comprehensive clinical evaluation that included cognitive evaluation (Mini-mental State Examination and Brief Cognitive Screening Battery), functional evaluation administered to a close relative, and a structured psychiatric evaluation (Mini International Neuropsychiatric Interview, MINI). Clinical diagnosis of AD was performed according to the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) work group criteria. Control subjects presented with no cognitive impairment or psychiatric diagnosis. None of the participants had inflammatory or autoimmune diseases and none had taken antibiotics or immunosuppressive drugs for at least 4 weeks before the study. sTNFR-1 was measured in plasma by ELISA following the manufacturer’s instructions (R&D Systems).

AβOs. Synthetic Aβ1–42 was used to prepare AβOs as described previously (Lambert et al., 1998). The peptide was first solubilized in HFIP and the solvent was evaporated to produce dried films. Films were then dissolved in sterile anhydrous DMSO to make a 5 mM solution, followed by dilution to 100 μM in ice-cold PBS and incubation for 16 h at 4°C. The preparation was centrifuged at 14,000 × g for 10 min at 4°C to remove any insoluble aggregates and the supernatants containing soluble AβOs were removed carefully and stored at 4°C. AβOs were used within 48 h of preparation. Protein concentration was determined using BCA kit.

Preparations were routinely characterized by HPLC size-exclusion chromatography under nonnondenaturing conditions and, occasionally, by SDS-PAGE/Western blot using anti-Aβ (6E10; Abcam) or anti-Aβ NU4 (Lambert et al., 2007) (kindly provided by Dr. William L. Klein, Northwestern University). AβO preparations were tested for endotoxin contamination using a commercial kit (Pierce) and showed no detectable levels of endotoxin (data not shown).

Animals, intracerebroventricular infusions, and other treatments. Three-month-old male Swiss mice were used. Animals were housed in groups of five per cage with ad libitum access to food and water under a 12 h light/dark cycle with controlled temperature and humidity. All procedures followed the Principles of Laboratory Animal Care from the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of the Federal University of Rio de Janeiro (protocol #IBqM 041/2011). For intracerebroventricular infusion of AβOs (or vehicle) (Figueiredo et al., 2013), animals were anesthetized for 7 min with 2.5% isoflurane (Crystalia) using a vaporizer system and gently restrained only during the injection procedure. A 2.5-mm-long needle was inserted unilaterally 1 mm to the right of the midline point equidistant from each eye and 1 mm posterior to a line drawn through the anterior base of the eyes. Ten picomoles of AβOs (or an equivalent volume of vehicle) were infused in a final volume of 3 μl. Accurate placement of the needle into the right lateral ventricle was confirmed by macroscopic examination of dissected brains. Mice showing any signs of misplaced injections or brain hemorrhage (~7% of animals throughout our study) were excluded from further analysis.

Minocycline, diluted in saline at pH 7.6, was administered by intraperitoneal injection (50 mg/kg/d) for 3 consecutive days ending on the day of AβO injection. Liposome-encapsulated sodium clodronate (5 mg of clodronate/ml of suspension, volume = 1.5 μl; ClodronateLiposomes.com or PBS-containing liposomes (used as a control) were administered intracerebroventricularly once 3 d before AβO infusion. Infliximab (0.2 μg in 2 μl) or saline (2 μl) was administered intracerebroventricularly 30 min before AβO infusion. Trycophan hydroxylase inhibitor (p-chlorophenylalanine; Sigma-Aldrich) was diluted in PBS and administered by intraperitoneal injection (250 mg/kg body weight) for 3 d before intracerebroventricular infusion of AβOs.

TLR4−/− mice and chimeric mice harboring a nonfunctional TLR4 mutation were maintained at the animal facility of the University of Campinas following procedures approved by the Institutional Animal Care and Use Committee of the University of Campinas (protocol #2397-1). In some experiments (see “Results”), APP/PS1 mice were used. These were bred and maintained in our animal facility and used at 8–9 months of age. Age-matched wild-type littermates were used as controls.

Forced swim test (FST). The FST was performed as described previously (Porsolt et al., 1977; Autry et al., 2011) with slight modifications. Mice were placed for 6 min in a 4 L Pyrex glass beaker containing 3 L of water at 24 ± 1°C. Water was changed between animals. A trained researcher blinded to group assignment recorded immobility time using a stopwatch. An increase in immobility time indicates depressive-like behavior.

Sucrose preference test. Mice were kept in individual cages and given a free choice between two bottles, one containing a 2% sucrose solution and another with plain water. The volume of consumed water and sucrose solution was measured daily. After preference for sucrose solution was reached (which typically took ~2–4 d), mice were infused intracerebroventricularly with AβOs, vehicle (2% DMSO in PBS), heat-denatured BSA, or scrambled Aβ peptide. After 24 h of recovery, sucrose preference...
was assessed as described above. Sucrose preference was expressed as the ratio between the volumes of sucrose solution or plain water consumed.

**Primary cultures of mouse microglia.** Primary microglial cultures were prepared as described previously (Azvedo et al., 2013). Mouse cortices were dissociated in culture medium containing DMEM/F12 supplemented with 10% fetal bovine serum and 1% gentamicin. Cells were incubated in 75 cm² flasks for 2 weeks at 37°C, 5% CO₂. After 2 weeks, microglia were isolated by shaking for 1 h in an orbital shaker and plated at 5 × 10⁵ cells/well in 96-well plates, 1 × 10⁴ cells/well in 24-well plates. Cultures were treated at 37°C for different time periods with 100 nM AβOs or an equivalent volume of vehicle (0.2% DMSO in PBS). E. coli lipopolysaccharide (LPS, 100 ng/ml) was used as a positive control for microglial activation. When present, 5-HT was added to cultures 30 min before AβOs. As noted above, AβO preparations tested negative for endotoxin contamination. In any case, as an added measure to ensure that experimental results were not affected by eventual and minor (below detection limit) endotoxin contamination in AβOs or other reagents, polymyxin B (10 µg/ml) was added routinely to the culture medium in all experimental conditions.

**Determination of TNF-α, sTNFR1, and nitric oxide (NO).** Whole brains or hippocampi were homogenized in PBS with protease and phosphatase inhibitors (Pierce) on ice and centrifuged at 15,000 rpm for 10 min at 4°C. Supernatants were collected for protein determination using BCA kit (Thermo Fisher Scientific). ELISA assays for TNF-α (BioLegend) or sTNFR1 (R&D Systems) were performed according to the manufacturer’s instructions.

TNF-α released by primary microglial cultures (5 × 10⁵ cells/well) during the 4 h period was measured using a kit in situ ELISA protocol. Plates were UV sterilized for 30 min and coated with anti-TNF-α monoclonal capture antibody (Peprotech) for 24 h at 25°C. Plates were washed 4 times with washing buffer (PBS, pH 7.2, containing 0.05% Tween 20) and blocked using 1% BSA for 1 h at 25°C. Microglia were then plated onto the wells and incubated for 1 h at 37°C, 5% CO₂. Cells were treated for 24 h with vehicle, LPS (100 ng/ml), AβOs (100 nM), or 5-HT (1 µM) or were pretreated with 5-HT (1 µM), followed by AβOs (100 nM). After 24 h, plates were washed extensively and incubated with anti-TNF-α polyclonal detection antibody conjugated with biotin (Peprotech) for 2 h at 25°C followed by streptavidin-HRP (Zymed) for 1 h at 25°C. Detection was performed using O-phenylenediamine (Sigma-Aldrich) and color development was monitored at 490 nm using an ELISA plate reader (SpectraMax Paradigm Reader; Molecular Devices). TNF-α levels were quantified using a recombinant TNF-α standard curve.

For NO determination, primary microglia cultures (5 × 10⁵ cells/well) were treated as described above for 48 h. Griess reagents (1% sulfanilamide and 0.1% naphthylethylenediamine dihydrochloride; 100 µM) were added to 100 µl of culture supernatants, homogenized, transferred to the original well, and further homogenized. Color development was monitored using an ELISA plate reader at 540 nm and micromolar nitrite levels were estimated using a sodium nitrite standard curve.

**Immunocytochemistry.** Cells were fixed in 4% paraformaldehyde for 20 min at room temperature and blocked in 10% normal goat serum diluted in PBS, incubated with anti-F4/80 mouse monoclonal antibody (1:50; AbDSerotec) or anti-Iba-1 rabbit polyclonal antibody (1:400; Wako) followed by Alexa Fluor-conjugated secondary antibodies (1:500; Invitrogen). Coverslips were imaged on a Zeiss Axio Observer Z1 microscope using 20× or 40× objectives.

**Immunohistochemistry.** Animals were anesthetized and perfused with saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Fixed brains were removed and cryoprotected in increasing concentrations of sucrose. Frozen 40 µm coronal brain sections were made on a cryostat (Leica Microsystems) and stored in Tris-buffered saline, 0.05% sodium azide, 30% glycerol, and 15% sucrose at 4°C. Free-floating immunohistochemistry was performed after washing the sections extensively with PBS. Sections of 5–7 sections per animal were incubated in 15 mm wells for 2 h with 0.25% Triton X-100, 3% BSA, and 3% normal donkey serum. After this blocking step, sections were incubated overnight with anti-Iba1 primary antibody (1:500; Wako) diluted in PBS. Sections were then washed and incubated for 2 h with an Alexa Fluor 594-conjugated secondary antibody (1:800; Life Technologies). After a final washing step, sections were briefly stained with DAPI and mounted with n-propyl galate. Images were acquired on a TE2000 Nikon microscope.

**Brain levels of 5-HT.** 5-HT levels in mouse brains were measured by HPLC coupled with electrochemical detection (HPLC-ED; Shimadzu). Briefly, animals were decapitated and brains dissected in ice-cold PBS. Perchloric acid was added to each sample to a final concentration of 0.1 M. Samples were sonicated (2 × 5 s pulses, 50 Hz) and centrifuged (14,000 × g, 10 min) to remove precipitated proteins. Protein quantification was further measured using BCA kit. Supernatants were used for HPLC-ED analysis. Isocratic separation was performed on a reverse-phase LC-18 column (4.6 mm × 250 mm; Sigma-Aldrich) using 20 ml Na2HPO4, 20 m NTs acid, 10% methanol, 0.12 m Na2EDTA, and 566 m Leptansulfonic acid, pH 2.64, as mobile phase.

**NF-κB assay.** Primary mouse microglia (10⁵ cells) were plated in 24-well plates. Cells were incubated with 100 nM AβOs or an equivalent volume of vehicle for 2 h, fixed in 4% paraformaldehyde, incubated in blocking/permeabilizing solution (PBS containing 5% normal goat serum and 0.3% Triton X-100) for 1 h at room temperature, and incubated overnight at 4°C with rabbit anti-mouse NFκB p65 (1:50 dilution; Cell Signaling Technology). followed by incubation with Alexa Fluor 546-conjugated goat anti-rabbit IgG (1:500; Cell Signaling Technology) for 1 h at room temperature. A total of 20 images were acquired per experimental condition in each of four independent experiments with different microglial cultures.

**RT-PCR.** Total RNA was isolated using the SV RNA isolation kit (Promega) according to manufacturer’s instructions. Reverse transcription was performed using the High-Capacity cDNA reverse transcription kit (Life Technologies) according to the manufacturer’s instructions using a thermocycler (AmplitiTherm TX25; Ideal Lab). PCR amplification using specific primer sets (Table 1) was performed at 95°C for 10 min and 15 s, 60°C for 1 min, 95°C for 15 s, 60°C for 1 min, and 95°C for 1 s, repeated for 40 cycles in a 7500 Real Time PCR System (Applied Biosystems). 18S ribosomal RNA was used as a control to evaluate relative expression of all other genes. mRNA levels are expressed using the 2⁻ΔΔCt method (Schnitten and Livak, 2008). Primer sequences used for PCR are shown in Table 1.

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Forward primer (3' → 5')</th>
<th>Reverse primer (3' → 5')</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBS</td>
<td>CGG CGG CCA TGT CTC TAG T</td>
<td>CAT GAT ATC TCC GCC CC</td>
</tr>
<tr>
<td>GATA1</td>
<td>CCT TGT GAG GCC AGA GAG TG</td>
<td>CCG CAG ATG GTT GTA GGT GT</td>
</tr>
<tr>
<td>ldo 1</td>
<td>TGG TCG AAG TAG CTT CT</td>
<td>TCC CAG CCC CCA TAC AG</td>
</tr>
<tr>
<td>ST100A10 (p11)</td>
<td>ATG GCA TCC AAA ATG GAC A</td>
<td>GCC ATCC TTG CAT GAG CA</td>
</tr>
<tr>
<td>TNF-α</td>
<td>GCA CAC ACA ATT GCA AGA</td>
<td>ACT ACG TGG GCT ACA G</td>
</tr>
<tr>
<td>BDNF</td>
<td>TAA ATG AAG TTT ATA CAG TAC AG</td>
<td>AGT GAT GCC GAA ATG ACT GTT</td>
</tr>
</tbody>
</table>

**Irradiation and bone marrow transplantation (BMT).** Six week-old male C3H/HeJ (Hj, TL4-R4-mutant; Poltorak et al., 1998) or C3H/HePas (HP, WT) mice were exposed to a single 8 Gray session of total body irradiation using a cobalt-60 source (Theratron-780 model; MDS Nordion). Twenty-four hours after irradiation, each animal was injected via the tail vein with at least 5 × 10⁶ bone marrow cells freshly collected from a donor mouse. Cells were aseptically harvested by flushing donor femurs with Dulbecco’s PBS (DPBS) containing 2% PBS, followed by filtration through a 40 µm nylon mesh and centrifugation at room temperature for 10 min at 1000 rpm. Cells were resuspended in DPBS and 5 × 10⁶ cells in 200 µl of the cell suspension were injected per mice. Irradiated mice transplanted with this cell suspension were housed in autoclaved cages and treated with antibiotics (0.2 mg of trimethoprin/ml and 1 mg of sulfamethoxazole/ml) in the drinking water for 4 d before and 7 d after irradiation.

**Data analysis.** All in vitro and in vivo experiments (except for the BMT experiment, which was performed once with groups of six to eight mice per experimental condition) were performed three to six times using independent microglial cultures or different groups of animals and different AβO preparations. Immunofluorescence intensity data were ana-
Depressive-like behavior has been reported in transgenic models of AD (Filali et al., 2009; Frye and Walf, 2009; Romano et al., 2014). Here, we first extended those findings using APPSwe/PS1ΔE9 mice, a well characterized AD model (Fig. 1A,B). Consistent with findings in transgenic AD models, we reported recently that a single intracerebroventricular infusion of AβOs (10 pmol) induces depressive-like behavior and cognitive deficit in mice (Ledo et al., 2013). In an effort to elucidate the mechanisms underlying this effect, we initially investigated whether proteins implicated in depressive-like behavior in mice or in human depressive disorder might mediate the impact of AβOs. We examined the expression levels of p11 (also known as S100A10, nerve growth factor-induced protein 42C, calpactin I light chain, annexin II light chain; Svenningsson et al., 2006), BDNF (Schmidt and Duman, 2007; Anon, 2008), GATA-1 (an erythroid...
transcription factor) (Kang et al., 2012) and indoleamine-2,3-dioxygenase (Wichers et al., 2005; Dantzer et al., 2008) in mouse brains after intracerebroventricular infusion of AβOs. No changes in mRNA levels were detected for any of these proteins either 24 h (Fig. 1C) or 10 d (data not shown) after infusion. Interestingly, a robust increase in brain expression of TNF-α, a proinflammatory cytokine implicated in depressive behavior (Zhu et al., 2006; Dantzer et al., 2008) and recently found to mediate AβO-induced memory impairment in mice (Lourenço et al., 2013), was verified 24 h after infusion of AβOs (Fig. 1C). Increased brain expression of TNF-α persisted for 8 d after AβO infusion (data not shown). We further found increased hippocampal levels of TNF-α (Fig. 1D) and soluble TNF-α receptor 1 (sTNFR1; Fig. 1E) 5 h after infusion of AβOs in mice. Underlining the pathophysiological relevance of elevated TNF-α signaling in AD, significantly higher plasma levels of sTNFR1 were verified in AD patients compared with age-matched healthy subjects (Fig. 1F).

We next sought to determine whether elevated brain TNF-α levels triggered depressive-like behavior in mice. Intracerebroventricular treatment of mice with infliximab, a TNF-α neutralizing monoclonal antibody, blocked depressive-like behavior induced by AβOs, as assessed by both the FST and sucrose preference test (Fig. 1G,H). Control experiments showed that intracerebroventricular infusion of aggregated (heat-denatured) BSA or scrambled Aβ did not induce anhedonic behavior in the sucrose preference test (data not shown).

Immunohistochemical analysis revealed a dramatic increase in density of Iba-1-positive cells in the hippocampi of AβO-infused mice (Fig. 1I,J). We thus investigated whether activated microglia were the source of elevated brain TNF-α levels in AβO-infused mice. Pretreatment of mice with minocycline, an inhibitor of microglial polarization to a more proinflammatory state (classically described as the M1 state (Kobayashi et al., 2013; Bie et al., 2014), blocked the increase in brain TNF-α mRNA levels induced by AβOs (Fig. 1K). Minocycline treatment further prevented the increase in immobility time in the FST (Fig. 1L) and the decrease in sucrose preference (Fig. 1M) induced by AβOs.

To further investigate the role of microglia in depressive-like behavior induced by AβOs, we performed selective ablation of microglia in mice using liposome-encapsulated sodium clodronate (van Rooijen and Hendrikx, 2010). Mice received a suspension of clodronate-containing liposomes (or PBS-containing liposomes as a control) delivered intracerebroventricularly 3 d before the infusion of AβOs. Clodronate treatment blocked the increase in Iba-1-positive cells induced by AβOs (Fig. 1N,O). AβOs failed to induce an increase in immobility time in the FST in clodronate-treated mice (Fig. 1P). Results thus suggest that microglia are the source of TNF-α production and mediate depressive-like behavior induced by AβOs.

Disruption of serotonergic signaling by AβOs contributes to brain inflammation

Serotonergic neurotransmission is compromised in major depression disorder and in AD (Bonaccorso et al., 1998; Anon, 2008; Rodriguez et al., 2012). Nonetheless, whereas the role of 5-HT is well established in depression, the relationship between deregulated 5-HT signaling and AD is not well understood. We hypothesized that neuroinflammation triggered by AβOs might lead to altered 5-HT levels. To test this hypothesis, we measured brain 5-HT levels in AβO-infused mice. Compared with vehicle-injected mice, levels of 5-HT were reduced significantly 10 d after infusion of AβOs in both hippocampus (Fig. 2A) and prefrontal cortex (Fig. 2B), brain regions affected in AD and depression. Minocycline treatment blocked this decrease (Fig. 2C). Results indicate that AβOs disrupt 5-HT homeostasis in a microglia-dependent manner.

We next investigated whether, conversely, 5-HT might counteract the deleterious impact of AβOs. To address this question, we injected 5-HT (100 pmol) or an equivalent volume of saline intracerebroventricularly in mice 30 min before intracerebroventricular infusion of AβOs and analyzed TNF-α levels in brain extracts 4 h later (Fig. 2D). Interestingly, pretreatment with 5-HT blocked the increase in brain TNF-α levels induced by AβOs. We further sought to determine whether endogenous 5-HT signaling regulates TNF-α levels in a physiological range. We measured levels of TNF-α in brain extracts from mice treated intraperitoneally with saline or PCPA, an inhibitor of tryptophan hydroxylase, the enzyme that catalyzes the rate-limiting step in 5-HT synthesis. Inhibition of 5-HT production increased TNF-α levels in the mouse brain (Fig. 1E).

5-HT prevents AβO-induced activation of microglia

The results presented above established that AβOs activate microglia in vivo. However, whether activation was caused by a direct impact of AβOs on microglia or if it was mediated by signaling from other cell types, notably neurons, remained to be determined. To gain insight into this question, we exposed purified primary cultures of mouse microglia to a low concentration of AβOs (100 nM). Live/dead labeling of microglial cultures showed no indication of cell death upon exposure to AβOs for up to 24 h (data not shown). Exposure of cultures to AβOs for 24 h induced marked morphological changes, with increased cell area...
and acquisition of amoeboid morphology revealed by immunostaining with anti-F4/80, indicating microglial polarization to an activated state (Fig. 3A, B). AβOs-induced morphological changes were prevented by prior treatment of cultures with 1 μM 5-HT (Fig. 3C–E). Similar results were obtained using integrated F4/80 immunofluorescence as an indicator of microglial activation (Fig. 3F).

We next measured TNF-α expression in microglial cultures and its release to the culture medium. Consistent with microglial activation, TNF-α mRNA levels were increased in cells exposed for 2 h to AβOs (Fig. 3G) and this was followed by increased levels of TNF-α and nitric oxide in the medium after 24 h of exposure to AβOs (Fig. 3H, I). This proinflammatory response was blocked fully by pretreatment of cultures with 5-HT (Fig. 3H, I).

We demonstrated recently that AβOs induce activation of IκB kinase in hippocampal neurons (Bomfim et al., 2012), which leads to activation of NFκB signaling. Nuclear translocation of NFκB activates transcription of several inflammation-related genes, including TNF-α. To further characterize the activation of microglia by AβOs, we investigated whether AβOs induced NFκB translocation to the nucleus. Exposure of microglial cultures to AβOs induced a marked increase in NFκB p65-positive nuclei (Fig. 4). Pretreatment of cells with 5-HT prevented the translocation of NFκB to the nucleus (Fig. 4J–M). These findings demonstrate that AβOs activate microglia directly, triggering nuclear translocation of NFκB and increased TNF-α production and release. Results further indicate a novel action of 5-HT in blocking microglial activation and counteracting the impact of AβOs.
Abnormal activation of microglial TLR4 underlies AβO-induced depressive-like behavior

Glial cells expressing high levels of TLR4 have been found surrounding plaques in AD brains and TLR4 levels are significantly increased in the brains of transgenic mouse models of AD (Heneka et al., 2014; Trotta et al., 2014; Heneka et al., 2015). Moreover, TLR4 expression has been reported to increase neuronal vulnerability to damage induced by fibrillar preparations of Aβ (Walter et al., 2007). These findings prompted us to investigate the involvement of TLR4 in microglial activation and depressive-like behavior induced by AβOs. Significantly, AβOs failed to induce increased immobility in the FST and anhedonic behavior (decreased preference for sucrose over water) in TLR4−/− mice (Fig. 5A, B). Lack of TLR4 further prevented the decrease in 5-HT levels in the hippocampus of mice infused with AβOs (Fig. 5C).

Finally, to determine the specific role of TLR4 in myeloid cells in depressive-like behavior, we used chimeric mice in which cells of myeloid lineage were replaced by cells derived from CH3/HeJ mice harboring a spontaneous loss-of-function mutation that renders TLR4 unresponsive to LPS (Poltorak et al., 1998). Remarkably, such animals were completely resistant to the increase in immobility time in the FST induced by intracerebroventricular infusion of AβOs (Fig. 5D), establishing that abnormal TLR4 activation underlies AβO-induced depressive-like behavior in mice.

Discussion

Although clinical and epidemiological studies have revealed a strong connection between AD and depression, the mechanisms connecting these disorders at the molecular and cellular levels remain to be elucidated. Here, we show that AβOs, which were linked previously to neuronal dysfunction and memory impairment in AD, induce depressive-like behavior in mice through TLR4-dependent microglial activation and aberrant TNF-α signaling. These results provide insight into the biological mechanisms underlying the clinical link between AD and depression.
A large body of evidence indicates that depression is associated with chronic, low-grade inflammation (Dantzer et al., 2008). Inflammation is a complex process and involves both soluble factors and specialized cells that are mobilized to neutralize threats and restore normal body physiology. In the brain, glial cells, especially astrocytes and microglia, undergo activation under proinflammatory conditions, increasing the production of proinflammatory cytokines. Chronic inflammation becomes deleterious and leads to progressive brain damage and neurodegeneration (Wyss-Coray and Mucke, 2002; Heneka et al., 2014, 2015), playing a critical role in the pathogenesis of AD. Consistent with our finding of increased TNF-α levels in the brains of mice infused intracerebroventricularly with AβOs, several studies have demonstrated the presence of inflammatory markers in the AD brain, including elevated levels of cytokines/chemokines and gliosis (notably microgliosis) in damaged regions (Czirr and Wyss-Coray, 2012; Wyss-Coray and Rogers, 2012; Heneka et al., 2014, 2015). Moreover, a recent meta-analysis indicated that blood concentrations of several inflammatory mediators, including TNF-α, IL-6, and IL-1β, are increased in AD patients (Swardfager et al., 2010), which is consistent with our finding of elevated levels of circulating sTNFR1, a proxy of TNF-α signaling, in the plasma of AD patients. Current results further revealed increased brain levels of sTNFR1 after intracerebroventricular infusion of AβOs in mice. It is also noteworthy that patients with major depressive disorder exhibit elevated levels of circulating sTNFR1 (Grassi-Oliveira et al., 2009), supporting the notion that aberrant TNF-α signaling provides a mechanistic link between AD and depression.

We further considered the possibility that additional proteins implicated in depression in humans or in depressive-like behavior in animal models might be affected by AβOs in the mouse brain. However, we could not detect any changes in expression of p11, BDNF, Ido-1, or Gata-1 in the brains of oligomer-injected mice, indicating that AβOs deregulated TNF-α signaling selectively. In the brain, TNF-α is mainly secreted by microglia in response to trauma, infection, or abnormal accumulation of protein aggregates (Park and Bowers, 2010). Significantly, we demonstrated recently that AβOs induce astrocytic and microglial activation in the brains of mice (Ledo et al., 2013) and macaques (Forny-Germano et al., 2014). Consistent with a central role of microglia in behavioral changes induced by AβOs, microgial ablation or pharmacological inhibition of microglial polarization to a proinflammatory state blocked behavioral alterations induced by AβOs in mice.

Previous studies have shown that proinflammatory cytokines alter the metabolism of 5-HT (Tuglu et al., 2003; Wichers et al., 2005; Tyring et al., 2006; Zhu et al., 2006; Dantzer et al., 2008), a neurotransmitter closely associated with depressive behavior (Nestler et al., 2002). Altered 5-HT levels and serotonergic signaling have also been implicated in AD (Zarro et al., 2005; Kepe et al., 2006; Lorke et al., 2006; Lezoualch, 2007; Cirrito et al., 2011; Goldenhuy and Van der Schyf, 2011). The current results established that AβOs reduced 5-HT levels in the mouse brain and this effect was prevented by minocycline treatment, implicating microglia in deregulated serotonergic signaling. Moreover, reducing brain 5-HT levels using a selective inhibitor of tryptophan hydroxylase led to increased brain levels of TNF-α in mice. We further found that 5-HT blocked AβO-induced microglial activation in vitro and, notably, the increase in brain TNF-α levels in oligomer-injected mice. These findings point to a novel key role of 5-HT in the physiological regulation of microglial activation and in pathological AβO-induced brain inflammation in AD.
Supporting this connection, recent studies have shown that 5HT(2A) receptor agonists exhibit anti-inflammatory actions (Yu et al., 2008; Nau et al., 2013). It appears, therefore, that a cross talk between serotonergic signaling and brain innate immunity plays a major role in regulating inflammation and its consequences in both physiological conditions and in the pathophysiology of AD or depression.

The mechanism by which AβOs reduce 5-HT levels remains unknown. It is possible, for example, that AβO-induced inflammation modulates the levels or activity of an enzyme involved in 5-HT metabolism. A plausible target is Ido-1, which diverts tryptophan to the kynurenine pathway, thus decreasing 5-HT metabolism. A plausible target is Ido-1, which diverts tryptophan to the kynurenine pathway, thus decreasing 5-HT metabolism.

Moreover, APP-transgenic mice, which accumulate AβOs in the brains of AβO-infused mice, is possible that AβOs upregulate Ido-1 activity without affecting its mRNA levels. Although the precise mechanism by which AβOs decrease brain 5-HT levels remains to be elucidated, recent data suggest that 5-HT deficiency increases stress vulnerability and impairs the antidepressant response after psychosocial stress (Sachs et al., 2015).

TLRs are transmembrane pattern recognition receptors that trigger signals in response to diverse pathogen-associated molecular patterns or damage-associated molecular patterns. It has been shown that TLRs, classically thought to respond to pathogen, can be activated in the absence of microbial infection (Wirleitner et al., 2003). Although we did not detect changes in expression of Ido-1 in the brains of AβO-infused mice, it is possible that AβOs upregulate Ido-1 activity without affecting its mRNA levels. Although the precise mechanism by which AβOs decrease brain 5-HT levels remains to be elucidated, recent data suggest that 5-HT deficiency increases stress vulnerability and impairs the antidepressant response after psychosocial stress (Sachs et al., 2015).

TLRs are transmembrane pattern recognition receptors that trigger signals in response to diverse pathogen-associated molecular patterns or damage-associated molecular patterns. It has been shown that TLRs, classically thought to respond to pathogens, can be activated in the absence of microbial infection (Wysy-Coray and Mucke, 2002) and regulate neurogenesis (Czirr and Wys-Coray, 2012). Glial cells surrounding Aβ plaques in AD brains express high levels of TLR4 (Walter et al., 2007; Okun et al., 2009). Moreover, APP-transgenic mice, which accumulate Aβ deposits progressively, exhibit significant increases in brain expression of TLR4 compared with their wild-type littermates (Walter et al., 2007) and TLR4 expression increases neuronal vulnerability to Aβ-induced damage (Tang et al., 2008). The current results show that the impact of AβOs on mouse behavior is abrogated in TLR4−/− mice and in chimeric mice harboring a nonfunctional missense mutated form of TLR4 selectively in cells of myeloid origin. Our results thus indicate that microglial TLR4 activation by AβOs triggers depressive-like behavior in mice.

Because the results presented here and in other studies point to inflammation as a central event in both depression and AD, it is tempting to speculate that anti-inflammatory drugs might be used to treat depression in AD. This proposal, however, should be regarded with caution. For example, Warner-Schmidt et al. (2011) have shown that ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) block the anti-inflammatory effects of selective serotonin reuptake inhibitors (SSRIs). In particular, NSAIDs abrogate the therapeutic actions of SSRIs by inhibiting the formation of brain TNF-α. Moreover, microglia are responsible for chemokine-mediated sensing and clearance of Aβ in the brain, so generalized inhibition of microglial function might be detrimental in terms of compromising Aβ clearance, promoting its oligomerization, and leading to increased neurotoxicity. Future studies are warranted to address the complexity of the interplay among brain inflammation, serotonergic signaling, and depressive behavior with the goal of determining ways to rebalance microglial activity to promote its beneficial actions and limit microglia-mediated damage.

A full understanding of how depression develops in AD remains a challenging problem that has been addressed by very few studies to date. Our findings raise the possibility that TLR4-dependent microglial activation, brain inflammation, and downregulation of 5-HT levels in response to AβOs contribute to the development of depression in AD. This may pave the way for the development of novel AD therapeutics aimed at boosting brain 5-HT levels and rebalancing microglial function.

References


• 12115
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267. CrossRef Medline


